European Psychiatry - Volume 33 - March 2016

771 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805 S767
EV1311
Long-acting injectable aripiprazole.
Clinical experience in a case series
J.M. Hernández Sánchez ∗, M.C. Cancino Botello ,
M.F. Molina López , D. Pe˜na Serrano , M. Machado Vera
1 Valencia, Spain
2 Hospital General de Valencia, Psychiatry, Valencia, Spain
∗ Corresponding author.
Introduction The use of long-acting injectable antipsychotics is
useful in patients with low therapeutic compliance.
Objective To present the demographic and clinical data of a case
series in which long-acting injectable aripiprazole has been pre-
scribed in an ambulatory Mental Health Center.
Methods Systematic review of the related literature and clinical
history of patients in which long-acting injectable aripiprazole had
been prescribed from January to March 2015 in a Mental Health
Center.
Results We found 10 patients, whose diagnosis were schizophre-
nia (4), non-specified psychosis (2), personality disorder (1), bipolar
disorder (1), schizoaffective disorder (2), of whom 7 were men and
3women, with amean age of 43.8 years old. Themean of years since
diagnosiswas 15.1 years. In 7 patients, we found concomitant treat-
ment with another antipsychotic agent (low dose quetiapine in all
of them); antidepressants in 1 patient, benzodiazepines in 6; mood
stabiliser in 5 and biperidene in 1. In relation to previous antipsy-
chotic drugs, we found: aripiprazole 15mg/day oral (4); long-acting
injectable paliperdidone 150mg/28 days (2) paliperdone 6mg/day
oral (1); combination of paliperidone 6mg/day oral plus olanzapine
5mg/day oral (1). Only 4 patients had used long-acting injectable
drugs previously in their lifetime. The reason of having initiated
treatment with long-acting injectable aripiprazole was sexual dis-
turbance (3); lack of compliance (4); clinical inestability (2) and
motor side effects (1).
Conclusions In our series, we can observe a chronic patient pro-
file, predominantly men with diagnosis of psychotic spectrum.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1312
Uncommon effects of clozapine
J. Jerónimo ∗, J. Santos , L. Bastos
Santa Maria’s Hospital, CHLN, Psychiatry and Mental Health
Department, Lisboa, Portugal
∗ Corresponding author.
Introduction Clozapine is the first option for treatment-resistant
schizophrenia, affecting about 20–30% of all patients. Weight gain,
sedation, hypotension and hypersalivation are common and well-
known adverse effects associatedwith clozapine. However, it is also
important to be aware of uncommon adverse effects, like parotitis.
Objective We report a case of clozapine-induced parotitis.
Methods Literature was accessed through Pudmed, using the
search terms parotitis and clozapine.
Results A 36-year-old male with paranoid schizophrenia, whose
psychotic symptoms have responded only slightly to two antipsy-
chotic trial, with both haloperidol and olanzapine. Therefore,
he began treatment with clozapine with the dose titrated to
400mg/day. At first, the only registered adverse effect was hyper-
salivation. Eventually, after 3 months of treatment, he developed
a unilateral swelling of the left parotid gland. Bacterial and viral
parotitis were ruled out and the diagnosis of clozapine-induced
parotitis was evoked. Patient scored 5 in the Parotitis-Specific
Criteria Modified Naranjo Probability Scale. Symptomatic med-
ication was initiated with paracetamol and a non-steroidal
anti-inflammatory with a favorable outcome.
Conclusion There are few reports of clozapine-induced paroti-
tis, a very rare and poorly known adverse effect with an unknown
pathophysiology. Early recognition and proper management are
essential to reduce morbidity associated with the treatment. There
is no consensus how to manage these adverse effect, however, gen-
erally it is not necessary to discontinue the treatment.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1313
Development and psychometric
testing of a Scale for Evaluating
Self-management Needs of Knee
Osteoarthritis (SMNKOA) in Taiwan
M.H. Kao ∗, Y.F. Tsai
1 Mackay Junior College of Medicine, Nursing, and Management,
Department of Nursing, New Taipei City, Taiwan
2 College of Medicine, Chang Gung University, School of Nursing,
Tao-Yuan, Taiwan
∗ Corresponding author.
Introduction Knee OA is a chronic and multifactorial disease;
self-management needs are complex, which requires a multi-
dimensional management plan. There is a need for healthcare
providers to provide patients with knowledge of knee OA and how
to effectively manage the disease.
Objective Self-management-needs scales are onemeans of deter-
mining the management requirements of an individual patient.
There is no suitable instrument available for assessing self-
management needs of adult patients with knee OA in Taiwan.
This study developed an instrument that could assess the self-
management needs of knee OA patients using Orem’s self-care
theory as a theoretical framework.
Aims This study developed and psychometrically tested a new
instrument for measuring adult patients’ self-management needs
of knee OA (SMNKOA).
Methods Development of the instrument involved three phases:
item generation and scale development; content and face validity
of the initial instrument; and evaluation of validity and reliabil-
ity of the new instrument. Participants (n = 372) were purposively
sampled from orthopaedic clinics at medical centres in Taiwan.
Results The self-care theory guided the development of the 35-
item SMNKOA scale. The content validity index was 0.83. Principal
components analysis identified a 3-factor solution, accounting for
53.19% of the variance. The divergent validity was –0.67; conver-
gent validity was –0.51. Cronbach’s was 0.95, Pearson correlation
coefficient was 0.88, and the intraclass correlation coefficient was
0.95.
Conclusions The SMNKOA scale can measure and identify the
individual self-management needs of knee OA patients. It will help
healthcare providers better evaluate strategies that can help these
patients cope with this chronic disease.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1314
Some side effects of antipsychotics
L. Montes Reula ∗, A. Ballesteros Prados
1 Red Salud Mental Gobierno de Navarra, CHN Psychiatric, Pamplona,
Spain
2 Red Salud Mental Gobierno Navarra, Mental Health Center, Estella,
Navarra, Spain
∗ Corresponding author.